Bioventus (NYSE:BVS) (NYSE: BVS) is a global medical device company specializing in orthobiologics and regenerative medicine solutions aimed at enhancing bone healing and joint health. Founded in 2012 and headquartered in Durham, North Carolina, the company develops and markets products that support non‐surgical and minimally invasive treatment options for patients suffering from musculoskeletal injuries and conditions. Bioventus has built a reputation for innovation by leveraging proprietary technologies and clinical evidence to advance patient outcomes across a range of indications.
The company’s core product portfolio includes EXOGEN®, a low‐intensity pulsed ultrasound system designed to accelerate fracture healing, and HYLAURONATE injectable therapies such as Durolane® and MONOVISC®, which are used for viscosupplementation in osteoarthritis of the knee. These offerings are complemented by a robust research and development pipeline focused on novel delivery mechanisms, biologic agents, and next‐generation formulations. Bioventus emphasizes evidence‐based practice, supporting its products with extensive clinical studies and peer‐reviewed publications.
Bioventus operates across North America, Europe, Asia Pacific and select emerging markets through direct sales forces, distribution partners, and strategic alliances. Its products are utilized in hospitals, outpatient surgery centers and physician offices, enabling access to treatments for orthopedic surgeons, sports medicine physicians and podiatrists. The company also maintains a global logistics and support network to ensure timely product availability and training for healthcare professionals.
Under the leadership of a seasoned management team with deep expertise in the medical device and regenerative medicine industries, Bioventus continues to pursue strategic acquisitions and partnerships to broaden its clinical offerings and geographic reach. The company remains committed to its mission of making faster physical recovery a reality for patients worldwide through the development of scientifically validated, non‐opioid solutions that address pain, inflammation and tissue healing.
